Stay in touch
Prime news from our network.
#read
AbbVie invests around 150 million euros in the future of cutting-edge research
AbbVie is investing around 150 million euros in cutting-edge research at its Ludwigshafen site. Together with the Minister President of Rhineland-Palatinate, Malu Dreyer, and other guests, the company gave the official go-ahead for the construction of the central research and development building "LUnA" (LUdwigshafen's new working environment).
29/04/2024
The state-of-the-art building will house a good third of the more than 1,000 researchers and will be equipped with the latest infrastructure to meet the requirements of advancing laboratory automation and digital research.
The state-of-the-art building will house a good third of the more than 1,000 researchers and will be equipped with the latest infrastructure to meet the requirements of advancing laboratory automation and digital research.
The decision by AbbVie underlines the importance of the Ludwigshafen site in the company's global network. The company aims to develop new therapies for serious diseases such as cancer, Alzheimer's and immunological disorders. Completion of the research building is planned for 2027.
Prime Minister of Rhineland-Palatinate Dreyer welcomed the investment as a further step towards making Rhineland-Palatinate a leading location for biotechnology and life sciences. AbbVie emphasised the importance of innovation-friendly political framework conditions for Germany as a pharmaceutical location and underlined the role of Ludwigshafen as a centre of excellence for research and development as well as for the production of pharmaceuticals.The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.